en · de · es · pt
tb-500-notes.peptides6088.com › Wiki › Thymosin Beta-4 Fragment Identity — Quick Reference

Thymosin Beta-4 Fragment Identity — Quick Reference

By Editorial Desk · published 2025-07-21 · last reviewed 2025-09-09 · Wiki

The short version of synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-09-09 and is reviewed periodically as new material appears.

Thymosin Beta-4 Fragment Identity

No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.

TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.

Thymosin Beta-4 Fragment Background

Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.

TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.

Tb-500 at a glance

PropertyValueNotes
Molecular massApproximately 4963 Da for full-length thymosin beta-4Value applies to the parent protein; fragment products may differ
AppearanceWhite to off-white lyophilized powderTypical form of supplied synthetic peptide
SolubilityFreely soluble in waterPolar peptide; dissolves readily in aqueous buffer
Storage of dry powder−20 °C, desiccated, protected from lightStandard laboratory practice for peptides
Typical detection methodLiquid chromatography–tandem mass spectrometryUsed in purity testing and anti-doping analysis

Handling, Stability and Analytical Detection

Detection in biological samples relies on mass spectrometry, typically liquid chromatography coupled to tandem mass spectrometry after peptide extraction and enrichment. Intact peptides can also be confirmed by high-resolution mass measurement together with fragmentation data. Detection windows in urine are short because the peptide is degraded by proteases and cleared quickly, and concentrations are low. Many jurisdictions treat the compound as a prohibited substance in sport, grouped with peptide hormones and related factors, while it is not an approved therapeutic product. Identity and purity statements therefore rest on certificates of analysis, ideally issued by an independent laboratory.

Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.

Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.

Related pages on this site

Detection, Stability, and Regulatory Status

Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.

Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.

Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.

Thymosin Beta-4 Fragment Overview

TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.

Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.

Handling, Storage and Quality Checks

Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.

Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.

Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.

Notes from published material

== Works cited == Hudson, Rex A.; Hanratty, Dennis Michael, eds. (1991). Bolivia: a country study. Washington, D.C.: Federal Research Division, Library of Congress. This article incorporates text from this source, which is in the public domain.{{cite encyclopedia}}: CS1 maint: postscript (link)

The prognosis is worse in those with larger burns, those who are older, and females. The presence of a smoke inhalation injury, other significant injuries such as long bone fractures, and serious co-morbidities (e.g. heart disease, diabetes, psychiatric illness, and suicidal intent) also influence prognosis. On average, of those admitted to burn centers in the United States, 4% die, with the outcome for individuals dependent on the extent of the burn injury. For example, admittees with burn areas less than 10% TBSA had a mortality rate of less than 1%, while admittees with over 90% TBSA had a mortality rate of 85%. In Afghanistan, people with more than 60% TBSA burns rarely survive. The Baux score has historically been used to determine prognosis of major burns. However, with improved care, it is no longer very accurate. The score is determined by adding the size of the burn (% TBSA) to the age of the person and taking that to be more or less equal to the risk of death. Burns in 2013 resulted in 1.2 million years lived with disability and 12.3 million disability adjusted life years.

According to Ahmad Dallal, Abū Rayhān al-Bīrūnī states that "there is no observable evidence that rules out the possibility of vacuum". The suction pump was described by Arab engineer Al-Jazari in the 13th century, and later appeared in Europe from the 15th century. European scholars such as Roger Bacon, Blasius of Parma and Walter Burley in the 13th and 14th century focused considerable attention on issues concerning the concept of a vacuum. The commonly held view that nature abhorred a vacuum was called horror vacui. There was even speculation that even God could not create a vacuum if he wanted and the 1277 Paris condemnations of Bishop Étienne Tempier, which required there to be no restrictions on the powers of God, led to the conclusion that God could create a vacuum if he so wished. From the 14th century onward increasingly departed from the Aristotelian perspective, scholars widely acknowledged that a supernatural void exists beyond the confines of the cosmos itself by the 17th century. This idea, influenced by Stoic physics, helped to segregate natural and theological concerns. Almost two thousand years after Plato, René Descartes also proposed a geometrically based alternative theory of atomism, without the problematic nothing–everything dichotomy of void and atom.

British businessmen Hamish Harding and Shahzada Dawood, along with Dawood's son, Suleman, are confirmed as being aboard the missing submersible that disappeared during a voyage to see the wreck of the RMS Titanic two days earlier. 21 June – UK inflation figures for May 2023 show it remained higher than expected, at 8.7%. 22 June The Bank of England raises the official bank rate from 4.5% to 5%, the 13th consecutive rise, and a greater increase than economists had expected. The RMT announces three fresh days of strike action for 20, 22 and 29 July. 23 June Banks and building societies are summoned for a meeting with Jeremy Hunt as pressure grows on them to help people struggling with rising mortgage costs. A series of measures are agreed, offering more flexibility. Junior doctors in England announce a new five-day walkout from 13 to 18 July – the longest strike yet – over pay. Following a trial at Northampton Crown Court, Louis De Zoysa is convicted of the 2020 murder of police sergeant Matt Ratana. 24 June – The UK government holds an emergency COBRA meeting to discuss the Wagner Group rebellion in Russia. Sunak urges both sides to "be responsible and to protect civilians". 25 June A national technical fault affects the 999 service, meaning emergency services are unable to receive calls for around two hours. The service is fully restored by the evening. A spokesman for Sarah, Duchess of York says that she is recovering following surgery for breast cancer at King Edward VII's Hospital a few days earlier.

Two years earlier, she had developed a new process of using potatoes to make flour and alcohol, which subsequently lessened Sweden's reliance on wheat crops and decreased the risk of famine. 1751: 19-year-old Italian physicist Cristina Roccati received her PhD from the University of Bologna. 1753: American botanist Jane Colden was the only female biologist mentioned by Carl Linnaeus in his masterwork Species Plantarum. 1754: German physician Dorothea Erxleben was the first female to be awarded a doctor in medicine in Germany (University of Halle, then Kingdom of Prussia). She practiced medicine from 1747 to 1762 in Quedlinburg. 1755: After the death of her husband, Italian anatomist Anna Morandi Manzolini took his place at the University of Bologna, becoming a professor of anatomy and establishing an internationally known laboratory for anatomical research. 1757: French astronomer Nicole-Reine Lepaute worked with mathematicians Alexis Clairaut and Joseph Lalande to calculate the next arrival of Halley's Comet. 1760: American horticulturalist Martha Daniell Logan began corresponding with botanic specialist and collector John Bartram, regularly exchanging seeds, plants and botanical knowledge with him. 1762: French astronomer Nicole-Reine Lepaute calculated the time and percentage of a solar eclipse that had been predicted to occur in two years time. She created a map to show the phases, and published a table of her calculations in the 1763 edition of Connaissance des Temps. 1766: French chemist Geneviève Thiroux d'Arconville published her study on putrefaction.

Sources: en.wikipedia.org

Background from the literature

Critic Robert Christgau called it "an ominous, obsessive, tongue-in-cheek country-rock synthesis, absorbing rural and urban, traditional and contemporary, at point of impact." Parsons suffered from fear of flying and the band toured via train. The band members lost most of their money in a perpetual poker game and their concerts were met with bewilderment. Parsons was taking psilocybin and cocaine, so his performances were erratic. The most successful appearance was in Philadelphia, where the group opened for the reconstituted Byrds. Midway through their set, Parsons joined the headline act and fronted his former group on renditions of "Hickory Wind" and "You Don't Miss Your Water". After returning to Los Angeles, the group recorded "The Train Song", written during an increasingly infrequent songwriting session on the train and produced by 1950s R&B legends Larry Williams and Johnny "Guitar" Watson. Despite a request from the Burritos that the remnants of their publicity budget be diverted to the promotion of the single, it also flopped. During this period, Ethridge departed, saying that he did not share Parsons' and Hillman's affinity for country music. He was replaced by lead guitarist Bernie Leadon, while Hillman reverted to bass. By this time, Parsons's drug use had increased to the point where new songs were rare, and much of his time was spent partying with the Rolling Stones, who were in America finishing Let It Bleed. As the Stones prepared to play the nation's largest venues, the Burritos played to dwindling nightclub audiences.

== Screening == Because it can be difficult to measure weight-for-height Z scores (WHZ) frequently, screening is performed by physical exam, with careful examination of the child's feet to detect the presence of bilateral pitting edema. Screening for edema is essential for the diagnosis of kwashiorkor, since nearly two-thirds of kwashiorkor cases do not have evidence of acute wasting (i.e. mid-upper arm circumference (MUAC) < 125 mm, or WHZ < -2) when diagnosed with kwashiorkor.

Receptor binding – Most drugs exert their effects by binding to specific cell receptors (proteins on cell surfaces or inside cells) Dose-response relationship – Illustrated using drug-response curves, these relationships show the effect of different drug doses on the magnitude of a response. Therapeutic window – The range of doses between the minimum effective concentration and the minimum toxic concentration.

All the secondary ions generated in SIMS analysis originate from the topmost monolayers of the bombarded solid. This means that all different modes of SIMS analysis are basically surface analysis; secondary-ion emissions—atomic as well as molecular—reflect the chemical composition of the near-surface region of the bombarded solid. However, the intention of different SIMS analyses may be quite different. This depends on the erosion rate of the surface, which is controlled by the dose of the primary ions. It may be bulk analysis (dynamic SIMS) or a true analysis of originally uppermost monolayer of a condensed phase (static SIMS).

Nicergoline is an ergot alkaloid derivative that acts as a potent and selective α1A-adrenergic receptor antagonist. The IC50 of nicergoline in vitro has been reported to be 0.2 nM. The primary action of nicergoline is to increase arterial blood flow by vasodilation. Furthermore, it is known that nicergoline inhibits platelet aggregation. Studies have shown that nicergoline also increases nerve growth factor in the aged brain. In addition to the α1A-adrenergic receptor, nicergoline is an antagonist of the serotonin 5-HT1A receptor (IC50 = 6 nM) and shows moderate affinity for serotonin 5-HT2 and α2-adrenergic receptors and low affinity for the dopamine D1 and D2 and muscarinic acetylcholine M1 and M2 receptors.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.

Has any regulator approved TB-500 for medical use?

No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.

Why does TB-500 appear in anti-doping literature?

It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.

Network